After Failed Trials, Drug Company Pivots to Early-Stage Alzheimer’s

by | Feb 14, 2013 | Health & Healing

That was before J&J’s highly anticipated Alzheimer’s drug, bapineuzumab, failed to improve memory and thinking skills in closely watched clinical trials of people with mild to moderate forms of the disease.

Had it worked, the drug would have been the first to alter the course of Alzheimer’s, a fatal brain-wasting disease that affects 36 million people worldwide. It also would have meant billions of dollars in annual sales.

Instead, J&J and its partners, Pfizer and Elan, pulled the plug on the intravenous treatment after years of development.

Nevertheless, Manji, the Kenyan-born scientist who spent 15 years researching neuropsychiatric diseases for the National Institutes of Health, stands by his prediction.

The former chief of the NIH’s Mood and Anxiety Disorders Program, who recently met with computer experts at NASA to understand how best to untangle the web of disparate information on brain science, says there is nothing more complex than brain disorders.

“We shouldn’t expect it to be easy,” Manji, 53, who leads the company’s research efforts in Alzheimer’s, mood disorders, schizophrenia and pain conditions, said in an interview.

Like its rivals, J&J is preparing to pivot from testing drugs in people who already have dementia to early-stage patients, when drugs may have a better shot at working.

In November, J&J partnered with Japan’s Shionogi to gain access to Shionogi’s oral beta secretase, or BACE, inhibitor, a promising new class of drugs that aims to prevent the production of the Alzheimer’s-linked protein beta amyloid before it can form toxic clumps in people’s brains.

While J&J and its partners are retooling bapineuzumab into a more convenient shot formulation – instead of an IV – the company is also working on other approaches, including an amyloid-attacking antibody similar to bapineuzumab, called AAB003, and a vaccine that would enlist the help of an individual’s immune system to fight the disease.

Manji says the company remains committed to amyloid-clearing treatments. He expects doctors will need a whole menu of drugs to address the massive burden of Alzheimer’s, which is expected to affect 115 million people globally by 2050.

Earlier Treatment

Experts liken Alzheimer’s to heart disease, in which fatty plaques build up in the arteries for years before breaking loose, causing a stroke or heart attack.

“If someone comes into the ER with a heart attack and you give them a (cholesterol-lowering) statin drug for the first time, you are probably 15 years too late,” said Dr. Michael Rafii, an Alzheimer’s expert at the University of California at San Diego.

Likewise, with Alzheimer’s, when a patient enters the dementia phase, treatments that remove amyloid may be too little, too late. That may be what occurred with bapineuzumab, which showed signs that it was removing plaques but offered no cognitive benefit.

Late-stage studies of Eli Lilly and Co’s similar drug, solanezumab, also failed to help patients with mild-to-moderate Alzheimer’s, but when the results of two studies were combined, researchers saw a hint of benefit in people with mild disease.

Many experts believe BACE inhibitors would be ideal for very early-stage patients because they may prevent dementia from developing.

Lilly and Merck already have midstage trials under way for their BACE inhibitors, with safety results expected by early 2014. J&J is still working out the details, but Manji said he expects human trials of the Shionogi drug to start soon.

Unlike anti-amyloid drugs, such as bapineuzumab, that remove plaque after it has formed, BACE inhibitors focus on preventing the production of beta amyloid. The drugs are designed to keep the enzyme beta-secretase from chopping up a larger protein called amyloid precursor protein (APP) into bits that make up beta amyloid.

A study published in July in the journal Nature helped fuel enthusiasm for BACE inhibitors. It found that people who have a mutation in APP are protected from Alzheimer’s, and this gene affects the activity of BACE, suggesting that BACE inhibitors might work.

“It is almost like these people are born with natural BACE inhibition that seems to protect them,” Manji said.

Developing a beta secretase inhibitor has presented a number of challenges, including understanding how to get the drugs across the protective blood-brain barrier and into the right spot in the brain. But after a decade of research, Manji says there is optimism that “the BACE nut has been cracked.”

Manji said the challenge now is to block some of the enzyme’s activity, without causing unintended side effects.

“What we still don’t completely know is if you get into enough people, are there some off-target effects you will discover?”

Other Avenues

To test new drugs in people with earlier-stage Alzheimer’s, scientists have organized a series of prevention trials, enrolling people who are genetically predisposed to develop Alzheimer’s or whose tests suggest they have pre-symptomatic disease.

Two Roche drugs, crenezumab and gantenerumab, and Lilly’s solanezumab and its BACE drug are among the first to be tested in these trials. No J&J drugs will be part in these early trials, but Manji says the company will benefit.

“I think the whole field is going to learn so much about the disease and the trajectory and the progression, irrespective of what compound is being used,” he said.

Meanwhile, J&J has provided seed funding for a pilot study in people with Down syndrome, another population that is predisposed to develop dementia early.

Manji is excited about efforts with partner Pfizer to develop a vaccine that targets amyloid. He says the vaccine, now in midstage trials, has overcome some of the issues that scuttled development of a similar effort by Elan in 2002.

Manji thinks the quickest way for drug companies to find answers to problems like Alzheimer’s will be through alliances to share information about underlying disease biology.

“If we are willing to stay the course and work together, we will make progress,” he said.

CHARISMA NEWSLETTERS

Stay up-to-date with current issues, Christian teachings, entertainment news, videos & more.

The latest breaking Christian news you need to know about as soon as it happens.

Prophetic messages from respected leaders & news of how God is moving throughout the world. 


MORE FROM CHARISMA

Is He a God of Wrath or a God of Love?

Is He a God of Wrath or a God of Love?

Do you think the God of the Old Testament is a God of wrath, and the God of the New Testament is a God of love? The truth is that God is the same throughout the entire Bible. His wrath and His love are revealed in both the Old and the New Testaments. So why, then, did...

How You Can Have a Perfect Heart

How You Can Have a Perfect Heart

Your heart is the most important part of you. It’s not only a physical organ that keeps your blood pumping, but when the Bible refers to the heart, it’s talking about who you really are. Each person has an inner and an outer life. There’s the person we show to...

How the FBI Raid on Mar-a-Lago Is Spiritual Warfare

How the FBI Raid on Mar-a-Lago Is Spiritual Warfare

It's been a few days since the FBI raided President Donald Trump's home in Mar-a-Lago, and the Biden Administration has yet to explain to the American people why they did what's never been done in American history—the government raiding the home of a former president....

How the Holy Spirit Can Restore Your True Sanity

How the Holy Spirit Can Restore Your True Sanity

Most of my life I tried to avoid one thing—being crazy or insane. When I was growing up my mother had emotional issues and saw a psychiatrist regularly. She was on medication which only seemed to make her mood swings worse. She had high highs, and low lows. When I...

Israel Prophecy: The Enemy is Stirring an Unimaginable Conflict

Israel Prophecy: The Enemy is Stirring an Unimaginable Conflict

https://www.youtube.com/watch?v=KJFFqAgykmU A cease-fire between Israel and Palestinian militants took effect late Sunday in a bid to end nearly three days of violence that killed dozens of Palestinians and disrupted the lives of hundreds of thousands of Israelis,...

RECENT ARTICLES

Why Partial Obedience to God is Disobedience

My husband had a saying for our children growing up. “Partial obedience is disobedience.” He wanted them to understand that doing half the plan would not get them the full reward. Another reminder...
Kingdom Economics: Why is America Declining Spiritually So Quickly?

Kingdom Economics: Why is America Declining Spiritually So Quickly?

The Bureau of Labor Statistics released a surprisingly strong July Employment Report.  Total nonfarm employment was 528K (398K previously, 250K expected).  Private nonfarm employment was 471K (404K previously, 230K expected). The headline unemployment rate dropped to...

Can You Discern Spiritual Wind?

Can You Discern Spiritual Wind?

The wind is a funny thing. We do not know where it comes from nor where it goes. We cannot see it, but we can see and feel its effects. Wind can be gentle and refreshing, cold or hot, strong, and dangerous, and everything in between. When the wind blows, we must...

Messianic Rabbi: He That Has an Eye, Let Him Hear

Messianic Rabbi: He That Has an Eye, Let Him Hear

It is interesting that, as a Messianic rabbi the question I am asked most often by Christians is if I believe that they as Christians have to celebrate, or observe, the biblical Holy Days. They are usually asking about those days listed in Leviticus 23: Shabbat, Yom...

How the Holy Spirit Is Preparing America

How the Holy Spirit Is Preparing America

As the crackdown against Christianity in America grows, it is a cycle believers have seen before. While no one celebrates their religious freedom coming under attack, God has used this persecution to great effect throughout history. Over the centuries, there have been...

Dealing Effectively with the Dynamics of Change

Dealing Effectively with the Dynamics of Change

Change can be challenging. Some people look forward to change and embrace it. Some people dread change and try to avoid it. Since change is inevitable, so here are some of the dynamics surrounding change and the specific strategies to deal with change more...

God’s Holy Interruption Is Coming Soon

God’s Holy Interruption Is Coming Soon

This past weekend I preached at The Roads Church, a charismatic congregation located in the tiny town of Norris City, Illinois. Located amid cornfields, the population is only 1,325, but almost that many people visit the church on weekends. They come from all over...

Pin It on Pinterest

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]